PRZOOM - /newswire/ -
Monrovia, CA, United States, 2013/03/05 - Paula Jacobs, Associate Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute’s Cancer Imaging Program, to Speak at the 6th Imaging in Drug Discovery - GTCbio.com.
Paula Jacobs, Associate Director of Division of Cancer Treatment and Diagnosis at the National Cancer Institute’s Cancer Imaging Program, to speak on “Translational Molecular Imaging: Promises and Pitfalls” at GTC’s 6th Imaging in Drug Discovery and Development Conference (May 8-10, 2013 in Boston, MA)
Molecular imaging agents have great promise for investigating biology and for assisting in the development of new therapeutic drugs. However, many issues need to be addressed to reap the benefits. Developing imaging drugs is a difficult business model: imaging as an in vivo assay of molecular processes is challenging to standardize and validate and imaging in therapy development can founder with poor understanding of the therapeutic target or process. Funding to support trials can be difficult to find. Obtaining regulatory authorizations for clinical trials can be challenging, particularly when pairing an investigational molecular imaging probe with an investigational therapeutic drug. Imaging endpoints may or may not be acceptable to regulatory authorities for drug registration. This presentation will discuss the National Cancer Institute’s experience with non-proprietary investigational molecular probes in both imaging-only and imaging-therapy trial settings as well as a variety of regulatory strategies. A few unusual funding opportunities will be discussed.
Paula M. Jacobs, Ph.D. is the Associate Director in the Division of Cancer Therapeutics and Diagnostics at the National Cancer Institute, responsible for the Cancer Imaging Program. She came to work at the NCI after 30 years in the pharmaceutical and medical device industries, where she was a key developer of ultrasmall superparamagnetic iron oxide drugs as magnetic resonance imaging agents and iron replacement therapeutics. Dr. Jacobs serves on three NCI Experimental Therapeutics (NExT) committees to review and manage the projects chosen for development. Her industrial experience includes roles at Clinical Assays, a division of Baxter Travenol; Seragen, a small biotechnology firm; and Advanced Magnetics. Dr. Jacobs received her undergraduate degree in chemistry at the Massachusetts Institute of Technology and graduate degrees at Tufts University and Northeastern University. Her post-doctoral training was at Northeastern University, Massachusetts Institute of Technology, and Peter Bent Brigham Hospital/Harvard Medical School. She has published in the areas of organic chemistry, inorganic chemistry, magnetic resonance imaging, neuro-oncology and nephrology.
GTC’s 6th Imaging in Drug Discovery and Development Conference brings together experts from academia, government, and industry from the National Cancer Institute, Stanford University, City of Hope and the Beckman Research Institute, Yale School of Medicine, Pfizer, Biogen Idec, PerkinElmer, Eisai, Columbia University, Roche, Sanofi, Janssen, and many more to discuss the most current developments and applications to further advance their molecular imaging projects on drug discovery and development.
This conference is also part of the Drug Discovery Summit 2013, which consists of this track and three other tracks:
7th Drug Design and Medicinal Chemistry
3rd Epigenetics in Drug Discovery
Orphan Drugs Research and Commercialization